Cargando…

Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival

BACKGROUND: Cuproptosis is a novel form of cell death referred to as copper-dependent cytotoxicity. The regulation of proptosis is becoming an increasingly popular cancer treatment modality. To date, few studies have attempted to identify the cuproptosis-related long non-coding RNAs (CRLs). In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Feng, Wu, Xiaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186494/
https://www.ncbi.nlm.nih.gov/pubmed/37201038
http://dx.doi.org/10.21037/jgo-23-228
_version_ 1785042570818093056
author Liu, Feng
Wu, Xiaoyang
author_facet Liu, Feng
Wu, Xiaoyang
author_sort Liu, Feng
collection PubMed
description BACKGROUND: Cuproptosis is a novel form of cell death referred to as copper-dependent cytotoxicity. The regulation of proptosis is becoming an increasingly popular cancer treatment modality. To date, few studies have attempted to identify the cuproptosis-related long non-coding RNAs (CRLs). In this study, we sought to investigate the CRLs and construct a novel prognostic model for colorectal cancer (CRC). METHODS: The RNA-sequencing data of CRC patients were obtained from The Cancer Genome Atlas database. An analysis was conducted to identify the differentially expressed long non-coding RNAs, and a correlation analysis was performed to identify the CRLs. A univariate Cox analysis was conducted to select the prognostic CRLs. Based on a least absolute shrinkage and selection operator regression analysis, a prognostic signature comprising the 22 identified CRLs was constructed. A survival receiver operating characteristic curve analysis was conducted to evaluate the performance of the signature. Finally, an in vitro analysis was performed to investigate the function of lncRNA AC090116.1 in the CRC cells. RESULTS: A signature comprising 22 CRLs was developed. The patients in the training and validation sets were divided into the low- and high-risk groups and had significantly different survival probabilities. This signature had outstanding prognostic accuracy in predicting the 5-year overall survival of patients [training set, area under the curve (AUC) =0.820; validation set, AUC =0.810]. The pathway enrichment analysis showed that the differential genes between low and high groups were enriched in several important oncogenic- and metastatic-associated processes and pathways. Finally, the in vitro experiments showed that AC090116.1 silencing promoted the cuproptosis processes and suppressed cell proliferation. CONCLUSIONS: Our findings provided promising insights into the CRLs involved in CRC. The signature based on CRLs has been successfully devised to prognosticate the clinical outcomes and treatment responses in patients.
format Online
Article
Text
id pubmed-10186494
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-101864942023-05-17 Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival Liu, Feng Wu, Xiaoyang J Gastrointest Oncol Original Article BACKGROUND: Cuproptosis is a novel form of cell death referred to as copper-dependent cytotoxicity. The regulation of proptosis is becoming an increasingly popular cancer treatment modality. To date, few studies have attempted to identify the cuproptosis-related long non-coding RNAs (CRLs). In this study, we sought to investigate the CRLs and construct a novel prognostic model for colorectal cancer (CRC). METHODS: The RNA-sequencing data of CRC patients were obtained from The Cancer Genome Atlas database. An analysis was conducted to identify the differentially expressed long non-coding RNAs, and a correlation analysis was performed to identify the CRLs. A univariate Cox analysis was conducted to select the prognostic CRLs. Based on a least absolute shrinkage and selection operator regression analysis, a prognostic signature comprising the 22 identified CRLs was constructed. A survival receiver operating characteristic curve analysis was conducted to evaluate the performance of the signature. Finally, an in vitro analysis was performed to investigate the function of lncRNA AC090116.1 in the CRC cells. RESULTS: A signature comprising 22 CRLs was developed. The patients in the training and validation sets were divided into the low- and high-risk groups and had significantly different survival probabilities. This signature had outstanding prognostic accuracy in predicting the 5-year overall survival of patients [training set, area under the curve (AUC) =0.820; validation set, AUC =0.810]. The pathway enrichment analysis showed that the differential genes between low and high groups were enriched in several important oncogenic- and metastatic-associated processes and pathways. Finally, the in vitro experiments showed that AC090116.1 silencing promoted the cuproptosis processes and suppressed cell proliferation. CONCLUSIONS: Our findings provided promising insights into the CRLs involved in CRC. The signature based on CRLs has been successfully devised to prognosticate the clinical outcomes and treatment responses in patients. AME Publishing Company 2023-04-26 2023-04-29 /pmc/articles/PMC10186494/ /pubmed/37201038 http://dx.doi.org/10.21037/jgo-23-228 Text en 2023 Journal of Gastrointestinal Oncology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Liu, Feng
Wu, Xiaoyang
Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival
title Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival
title_full Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival
title_fullStr Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival
title_full_unstemmed Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival
title_short Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients’ survival
title_sort identification and validation of a novel cuproptosis-related lncrna signature for predicting colorectal cancer patients’ survival
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186494/
https://www.ncbi.nlm.nih.gov/pubmed/37201038
http://dx.doi.org/10.21037/jgo-23-228
work_keys_str_mv AT liufeng identificationandvalidationofanovelcuproptosisrelatedlncrnasignatureforpredictingcolorectalcancerpatientssurvival
AT wuxiaoyang identificationandvalidationofanovelcuproptosisrelatedlncrnasignatureforpredictingcolorectalcancerpatientssurvival